Furthermore, LPAR1 heterodimerises with C-X-C chemokine receptor type 4 (CXCR-4) and inhibits CXCL12-induced CXCR4 signalling, while LPA/LPAR1 blocks CXCL12/CXCR4-induced migration of triple-negative breast cancer cells [85]. Here, CXCR4 is linked to triple-negative breast carcinoma.